Bipolar disorder: Role of inflammation and the development of disease biomarkers

Psychiatry Investigation

Volumn 13, Issue 1, 2016, Pages 18-33

  Muneer, Ather ^a  

^a RIPHAH INTERNATIONAL UNIVERSITY   (Pakistan)

Author keywords

Biomarkers; Bipolar disorder; Cytokines; Inflammation; Neurotrophins

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; GLUTAMIC ACID DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LITHIUM; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ARTICLE; ATOPY; BIPOLAR DISORDER; ELECTROCONVULSIVE THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNCTIONAL DISEASE; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MOOD DISORDER; NERVE CELL PLASTICITY; PROTEIN EXPRESSION;

EID: 84956962598     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2016.13.1.18     Document Type: Article

References (105)

1. Fagiolini A, Forgione R, Maccari M, Cuomo A, Morana B, Dell’Osso MC, et al. Prevalence, chronicity, burden and borders of bipolar disor­der. J Affect Disord 2013;148:161-169.
2. Vieta E, Reinares M, Rosa AR. Staging bipolar disorder. Neurotox Res 2011;19:279-285.
3. Uher R. Gene-environment interactions in severe mental illness. Front Psychiatry 2014;5:48.
4. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011;131:101-104.
5. Hamdani N, Doukhan R, Kurtlucan O, Tamouza R, Leboyer M. Im­munity, inflammation, and bipolar disorder: diagnostic and therapeu­tic implications. Curr Psychiatry Rep 2013;15:387.
6. Gama CS, Kunz M, Magalhaes PV, Kapczinski F. Staging and neuro­progression in bipolar disorder: a systematic review of the literature. Rev Bras Psiquiatr 2013;35:70-74.
7. Bai YM, Su TP, Tsai SJ, Wen-Fei C, Li CT, Pei-Chi T, et al. Comparison of inflammatory cytokines levels among type I/type II and manic/hy­pomanic/euthymic/depressive states of bipolar disorder. J Affect Dis­ord 2014;166:187-192.
8. Stertz L, Magalhaes PV, Kapczinski F. Is bipolar disorder an inflam­matory condition? The relevance of microglia activation. Curr Opin Psychiatry 2013;26:19-26.
9. Watkins CC, Sawa A, Pomper MG. Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular im­aging to clinical application. Transl Psychiatry 2014;4:e350.
10. Brietzke E, Stabellini R, Grassi-Oliveira R, Lafer B. Cytokines in bipo­lar disorder: recent findings, deleterious effects but promise for future therapeutics. CNS Spectr 2011;16:157-168.
11. Bai YM, Su TP, Li CT, Tsai SJ, Chen MH, Tu PC, et al. Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls. Bipolar Disord 2015;17: 269-277.
12. Brambilla P, Bellani M, Isola A, Bergami A, Marinelli V, Dusi N, et al. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those of schizophre­nia. Transl Psychiatry 2014;4:e406.
13. Barbosa IG, Morato IB, de Miranda AS, Bauer ME, Soares JC, Teixeira AL. A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status. J Affect Disord 2014;157:41-44.
14. Doganavsargil-Baysal O, Cinemre B, Aksoy UM, Akbas A, Metin O, Fettahoglu C, et al. Levels of TNF-alpha, soluble TNF receptors (sTNF-R1, sTNF-R2) and cognition in bipolar disorder. Hum Psychopharma­col 2013;28:160-167.
15. Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, et al. In­terleukin 1 receptor antagonist and soluble tumor necrosis factor re­ceptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res 2013;145:36-42.
16. Remlinger-Molenda A, Wojciak P, Michalak M, Rybakowski J. Activi­ty of selected cytokines in bipolar patients during manic and depres­sive episodes. Psychiatr Pol 2012;46:599-611.
17. Remlinger-Molenda A, Wojciak P, Michalak M, Karczewski J, Ryba­kowski JK. Selected cytokine profile during remission in bipolar pa­tients. Neuropsychobiology 2012;66:193-198.
18. Kunz M, Cereser KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 2011;33:268-274.
19. Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorder but not in schizophrenia. J Psychiatr Res 2011;45:1608-1616.
20. Guloksuz S, Cetin EA, Cetin T, Deniz G, Oral ET, Nutt DJ. Cytokine levels in euthymic bipolar patients. J Affect Disord 2010;126:458-462.
21. Barbosa IG, Huguet RB, Mendonca VA, Sousa LP, Neves FS, Bauer ME, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011;261: 139-143.
22. Hope S, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, et al. Similar immune profile in bipolar disorder and schizophrenia: se­lective increase in soluble tumor necrosis factor receptor I and von Willibrand factor. Bipolar Disord 2009;11:726-734.
23. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant’anna M, Mascarenhas M, Escosteguy Vargas A, et al. Comparison of cytokine levels in de­pressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009;116:214-217.
24. Ortiz-Dominguez A, Hernandez ME, Berlanga C, Gutierrez-Mora D, Moreno J, Heinze G, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007;9:596-602.
25. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disor­der. J Affect Disord 2007;104:91-95.
26. O’Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006; 90:263-267.
27. Kim YK, Myint AM, Lee BH, Han CS, Lee SW, Leonard BE, et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res 2004;129:267-272.
28. Su KP, Leu SJ, Yang YY, Shen WW, Chou YM, Tsai SY. Reduced pro­duction of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. J Affect Disord 2002;71:205-209.
29. Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJ. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipo­lar mania. J Affect Disord 2001;64:185-193.
30. Munkholm K, BraunerJV, Kessing LV, Vinberg M. Cytokines in bipo­lar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013;47:1119-1133.
31. Prasad R, Kapoor R, Srivastava R, Mishra OP, Singh TB. Cerebrospi­nal fluid TNF-alpha, IL-6, and IL-8 in children with bacterial menin­gitis. Pediatr Neurol 2014;50:60-65.
32. Kontoangelos K, Papageorgiou CC, Raptis AE, Tsiotra P, Boutati E, Lambadiari V, et al. Cytokines, diabetes mellitus and psychopatholo­gy: a challenging combination. Neuro Endocrinol Lett 2014;35:159-169.
33. Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013;70:931-939.
34. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70:1078-1090.
35. Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. Cy­tokine levels in blood may distinguish suicide attempters from de­pressed patients. Brain Behav Immun 2011;25:335-339.
36. Soderlund J, Olsson SK, Sameulsson M, Walther-Jallow L, Johansson C, Erhardt S, et al. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci 2011;36:114-118.
37. Maletic V, Raison C. Integrated neurobiology of bipolar disorder. Front Psychiatry 2014;5:98.
38. Myint AM. Kynurenines: from the perspective of major psychiatric disorders. FEBS J 2012;279:1375-1385.
39. Jun C, Choi Y, Lim SM, Bae S, Hong YS, Kim JE, et al. Disturbance of the glutamatergic system in mood disorders. Exp Neurobiol 2014;23:28-35.
40. Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signal­ing in neuronal homeostasis and dysfunction. Cell Signal 2010;22: 977-983.
41. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopa­mine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 2012;33:315-327.
42. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Sameulsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide at­tempters and related to symptom severity. Biol Psychiatry 2009;66:287-292.
43. Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a me­diator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010; 7:243-250.
44. Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, Reperant C, et al. Behavioral and serotonergic consequences of decreasing or in­creasing hippocampus brain-derived neurotrophic factor protein lev­els in mice. Neuropharmacology 2008;55:1006-1014.
45. Patas K, Penninx BW, Bus BA, Vogelzangs N, Molendijk ML, Elzinga BM, et al. Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features. Brain Behav Immun 2014;36:71-79.
46. Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR 3rd, Lafaille JJ, et al. Microglia promote learning-dependant synapse formation through brain-derived neurotrophic factor. Cell 2013;155:1596-1609.
47. Yang J, Harte-Hargrove LC, Siao CJ, Marinic T, Clarke R, Ma Q, et al. proBDNF negatively regulates neuronal remodeling, synaptic trans­mission, and synaptic plasticity in hippocampus. Cell Rep 2014;7:796-806.
48. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006; 398:215-219.
49. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011;35:804-817.
50. Soares JC. Contributions from brain imaging to the elucidation of pathophysiology of bipolar disorder. Int J Neuropsychopharmacol 2003;6:171-180.
51. Maripuu M, Wikgren M, Karling P, Adolfsson R, Norrback KF. Rela­tive hypo- and hypercortisolism are both associated with depression and lower quality of life in bipolar disorder: a cross-sectional study. PLoS One 2014;9:e98682.
52. Drevets WC, Price JL, Furey ML. Brain structural and functional ab­normalities in mood disorders: implications for neurocircuitry mod­els of depression. Brain Struct Funct 2008;213:93-118.
53. Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiolo­gy and treatment of major depression. Brain Behav Immun 2007;21:9-19.
54. Havermans R, Nicolson NA, Berkhof J, deVries MW. Patterns of sali­vary cortisol secretion and responses to daily events in patients with re­mitted bipolar disorder. Psychoneuroendocrinology 2011;36:258-265.
55. Kamali M, Saunders EF, Prossin AR, Brucksch CB, Harrington GJ, Langenecker SA, et al. Associations between suicide attempts and ele­vated bedtime salivary cortisol levels in bipolar disorder. J Affect Dis­ord 2012;136:350-358.
56. Grossman F, Potter WZ. Catecholamines in depression: a cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH. Psychiatry Res 1999;87:21-27.
57. Latalova K, Prasko J, Diveky T, Grambal A, Kamaradova D, Velartova H, et al. Autonomic nervous system in euthymic patients with bipolar affective disorder. Neuro Endocrinol Lett 2010;31:829-836.
58. Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006;67:1034-1041.
59. Laursen TM, Wahlbeck K, Hallgren J, Westman J, Osby U, Ali­naghizadeh H, et al. Life expectancy and death by diseases of the cir­culatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One 2013;8:e67133.
60. Schroeter ML, Abdul-Khaliq H, Sacher J, Steiner J, Blasig IE, Mueller K. Mood disorders are glial disorders: evidence from in vivo studies. Cardiovasc Psychiatry Neurol 2010;2010:780645.
61. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001;49:741-752.
62. Bowley MP, Drevets WC, Ongur D, Price JL. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002;52:404-412.
63. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oli­godendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consor­tium. Schizophr Res 2004;67:269-275.
64. Gos T, Schroeter ML, Lessel W, Bernstein HG, Dobrowolny H, Schiltz K, et al. S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. J Psychiatr Res 2013;47:1694-1699.
65. Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007;94:273-280.
66. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. Im­munological aspects in the neurobiology of suicide: elevated microgli­al density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008;42:151-157.
67. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002;125:1428-1449.
68. Rajkowaska G. Cell pathology in mood disorders. Semin Clin Psychi­atry 2002;7:281-292.
69. Ongur D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen MB, et al. Abnormal glutamatergic neurotransmission and neuronal-glial inter­actions in acute mania. Biol Psychiatry 2008;64:718-726.
70. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62:1310-1316.
71. Yuksel C, Ongur D. Magnetic resonance spectroscopic studies of glu­tamate-related abnormalities in mood disorders. Biol Psychiatry 2010; 68:785-794.
72. Chitty KM, Lagopoulos J, Lee RS, Hickie IB, Hermens DF. A systemat­ic review and meta-analysis of proton magnetic resonance spectrosco­py and mismatch negativity in bipolar disorder. Eur Neuropsychophar­macol 2013;23:1348-1363.
73. Colla M, Schubert F, Bubner M, Heidenreich JO, Bajbouj M, Seifert F, et al. Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chron­ic lithium therapy and correlates inversely with diurnal cortisol. Mol Psychiatry 2009;14:696-704.
74. Scumpia PO, Kelly-Scumpia K, Stevens BR. Alpha-lipoic acid effects on glial functions accompanying double-stranded RNA antiviral and inflammatory signaling. Neurochem Int 2014;64:55-63.
75. Wang P, Zhu F, Konstantopoulos K. Prostaglandin E2 induces inter­leukin-6 expression in human chondrocytes via cAMP/protein kinase A- and phosphatidylinositol 3-kinase-dependant NF-kappaB activa­tion. Am J Physiol Cell Physiol 2010;298:C1445-C1456.
76. Lee HN, Surh YJ. Therapeutic potential of resolvins in the prevention and treatment of inflammatory disorders. Biochem Pharmacol 2012; 84:1340-1350.
77. Nahman S, Belmaker RH, Azab AN. Effects of lithium on lipopoly­sacchride-induced inflammation in rat primary glial cells. Innate Im­mun 2012;18:447-458.
78. Kang K, Kim YJ, Kim YH, Roh JN, Nam JM, Kim PY, et al. Lithium pretreatment reduces brain injury after intracerebral hemorrhage in rats. Neurol Res 2012;34:447-454.
79. Zhang Z, Zhang ZY, Wu Y, Schluesener HJ. Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats. Neuroscience 2012;221:140-150.
80. Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 2011;72:1577-1584.
81. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychia­try 2012;73:81-86.
82. Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W. Mi­nocycline and aspirin in the treatment of bipolar depression: a proto­col for a proof-of-concept, randomized, double-blind, placebo-con­trolled, 2x2 clinical trial. BMJ Open 2012;2:e000643.
83. Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O’Neil A, et al. Aspirin: a review of its neurobiological properties and therapeutic po­tential for mental illness. BMC Med 2013;11:74.
84. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, pla­cebo-controlled study. Hum Psychopharmacol 2008;23:87-94.
85. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, El­kind MS, et al. Criteria for evaluation of novel markers of cardiovas­cular risk: a scientific statement from the American Heart Associa­tion. Circulation 2009;119:2408-2416.
86. Munkholm K, Vinberg M, Vedel kessing L. Cytokines in bipolar disor­der: a systematic review and meta-analysis. J Affect Disord 2013;144:16-27.
87. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013;74:15-25.
88. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011;14:347-353.
89. Geller B, Badner JA, Tillman R, Christian SL, Bolhofner K, Cook EH Jr. Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early ado­lescent bipolar disorder phenotype. Am J Psychiatry 2004;161:1698-1700.
90. Lin PY. State-dependant decrease in levels of brain-derived neuro­trophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett 2009;466:139-143.
91. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar dis­order patients. Psychoneuroendocrinology 2014;47:199-211.
92. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapcszinski F, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007;61:142-144.
93. Fernandes BS, Gama CS, Kauer-Sant’Anna M, Lobato MI, Belmonte-de-Abreu P, Kapczinski F. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differ­ential diagnosis. J Psychiatr Res 2009;43:1200-1204.
94. Fernandes BS, Gama CS, Cereser KM, Yatham LY, Fries GR, Colpo G, et al. Brain-derived neurotrophic factor as a state-marker of mood ep­isodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011;45:995-1004.
95. Palomino A, Vallejo-Illarramendi A, Gonzales-Pinto A, Aldama A, Gonzalez-Gomez C, Mosquera F, et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006;86:321-322.
96. Grande I, Kapczinski F, Stertz L, Colpo GD, Kunz M, Cereser KM, et al. Peripheral brain-derived neurotrophic factor changes along treat­ment with extended release quetiapine during acute mood episodes: an open-label trial in drug-free patients with bipolar disorder. J Psy­chiatr Res 2012;46:1511-1514.
97. de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO, et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4 week study. Neurosci Lett 2011;494:54-56.
98. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.
99. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012;139:230-239.
100. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neurophychopharmacology 2011;36:2452-2459.
101. Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord 2014;169:15-20.
102. Bai YM, Chiou WF, Su TP, Li CT, Chen MH. Pro-inflammatory cyto­kines associated with somatic and pain symptoms in depression. J Af­fect Disord 2014;155:28-34.
103. O’Donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelle­her C, et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety 2013;30: 307-314.
104. Warner-Schmidt JL, Schmidt EF, Marshall JJ, Rubin AJ, Arango-Liev­ano M, Kaplitt MG, et al. Cholinergic interneurons in the nucleus ac­cumbens regulate depression-like behavior. Proc Natl Acad Sci U S A 2012;109:11360-11365.
105. Anisman H, Du L, Palkovits M, Faludi G, Kovacs GG, Szontagh-Kishazi P, et al. Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects. J Psy­chiatry Neurosci 2008;33:131-141.